Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters

Cheng-Hsien Hung; Tsung-Yuan Yang; James Cheng-Chung Wei

doi:10.1111/apt.16872

Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters

Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.

Authors

Cheng-Hsien Hung¹, Tsung-Yuan Yang^{2

3}, James Cheng-Chung Wei^{4

5

6}

Affiliations

¹ Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
² Department of Internal Medicine, Chung-Shan Medical University Hospital, Taichung, Taiwan.
³ School of Medicine, Institute of Medicine, Chung-Shan Medical University, Taichung, Taiwan.
⁴ Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
⁵ Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
⁶ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

Abstract

This article is linked to Kokkotis et al papers. To view these articles, visit https://doi.org/10.1111/apt.16717 and https://doi.org/10.1111/apt.16904

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
SARS-CoV-2
Tumor Necrosis Factor Inhibitors* / therapeutic use
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha